A paradigm shift in toxicological risk assessment: more science, less animal testing
Bas Blaauboer (Universiteit Utrecht, NL)

ALTERNATIVE TESTING STRATEGIES TO REDUCE ANIMAL USE IN PRECLINICAL DEVELOPMENT AT J&JPRD BELGIUM
Bas-Jan Van der Leede (Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica N.V., Genetic and Exploratory Toxicology, Turnhoutseweg 30, Beerse, BE)

In vitro liver toxicity predicts in vivo hepatoxicity using the microarray technique
Peter Olinga (Solvay Pharmaceuticals, Clinical Candidate Selection, Weesp / University Groningen, NL)

Optimal kinetic screening (in-vivo and in-vitro) and evaluation
Jessica Dijksman (Solvay Pharmaceuticals, Weesp, NL)

Recent Developments Towards Green Chromatography 
Pat Sandra (Research Institute for Chromatography (RIC), Kennedypark 26, B-8500 Kortrijk, B)

The Use of Dried Blood Spot Samples and Direct Analysis for the Quantitative Bioanalysis of Drugs
Paul Abu-Rabie (GlaxoSmithKline, Bioanalytical Science and Development, UK)

Evaluation of experimental drugs by bioanalysis: reduction of needed animals
Ben Westerink and Thomas IFH Cremers (Groningen Research Institute of Pharmacy, RUG and Brains-on-line BV, NL)

Whole blood analysis with LC-MS/MS using direct injection
Jaap Verweij (Schering-Plough, Toxicology and Drug Disposition, Oss, NL)

Addressing the Challenges of Limited Sample Volumes in Bioanalysis with Microscale LC-MS/MS
Paul Rainville (Waters, UK)

[ Program ] [ Abstracts ] [ Posters ] [ Submission ] [ Slides ] [ Hotels ] [ Directions ]
[ 2001 ] [ 2002 ] [ 2003 ] [ 2004 ] [ 2005 ] [ 2006 ] [ 2007 ] [ 2008 ] [ 2009 ]

Last update
04-Nov-09